Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

Small-cell lung cancer (SCLC) is a highly aggressive disease with dismal prognosis (1). Given its tendency to early develop widespread metastases, in approximatively two-thirds of cases SCLC is diagnosed at extensive-stage (ES). Standard treatment for ES-SCLC has remained unchanged for years.